Please login to the form below

Not currently logged in
Email:
Password:

Gilead EVP, Kevin Young, receives CBE

Kevin Young, executive vice president, Gilead Sciences has been awarded a CBE

Kevin Young, executive vice president, Gilead Sciences has been awarded a CBE "for services to the healthcare and pharmaceutical industries particularly to the development and marketing of life-changing medicines."
 
Young, originally from the north of England, is based at Gilead Sciences in California. Gilead provides the most frequently chosen antiretroviral medicines for the treatment of HIV in the developed world – the life-changing medicines referred to in the CBE citation.

Kevin Young, EVP Gilead Sciences
Kevin Young, EVP Gilead Sciences

 
Gilead's International Access Operations provide these medicines at a no-profit price to almost 100 low-income countries and at sharply discounted prices in a total of 130 developing countries. In total, 2.1 million people worldwide receive one of Gilead's HIV treatments, two thirds (1.4 million) are in the developing world. 

In the UK and Europe, Gilead is well known for Atripla (efavirenz tenofovir emtricitabine): its single tablet regimen (STR) for the treatment of HIV. Atripla is the only single tablet taken once a day that contains the triple-therapy required to successfully control the HIV virus and prevent progression to AIDS.  

13th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...
How Helpful are Simple Health Messages?
...

Infographics